Podcast | IL17Pod

Course Title for Certificate
Name*

First NameLast Name
Email*
example@example.com
MDRN/NPPAProfessorIndustryOther
How many years have you been in practice?
a. TNF-Interferon alpha-TYK2 pathwayb. Interleukin 23- TYK2-Interleukin 17 pathwayc. JAK1-JAK2-JAK3 pathwayd. Filagrin-Interleukin 4/13-JAK2/TYK2 pathwaye. All of the above
a. Elevation of only the IL-17A subtype in psoriasis lesionsb. IL-23 induces psoriasis in IL-17 knockout micec. IL-17A, C and F expression are decreased 8-fold in psoriasis lesionsd. Specific inhibitors of IL-17 are highly effective psoriasis treatmentse. Drugs that are effective for psoriasis and psoriatic arthritis are also effective for inflammatory bowel disease
a. Brodalumabb. Apremilastc. Isotretinoind. Bimekizumabe. None of the above
a. Use of IL-17 blockersb. Obesityc. Alcoholismd. A & Be. B & C
a. Serious infectionsb. Fungal infectionsc. Adjudicated MACEd. Malignancies excluding NMSC
a. Oral candidiasis rates are significantly higher in Week 16 PASI 100 responders than in the overall populationb. Oral candidiasis rates are similar across Week 16 PASI 100 responders, Week 48 responders, and the overall populationc. Oral candidiasis is not reported in PASI 100 responders but occurs at high rates in the overall populationd. Rates of oral candidiasis decrease over time only in the overall population, not in PASI 100 responders

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the MOA of IL-17 inhibitors and the biologic rationale for their use
Discuss the approved indications, use cases, and patient selection considerations for the use of IL- 17 inhibitors in dermatologic disease
Review and contextualize new information from EADV 2025 on the long-term monitoring of specific adverse effects attributed to IL- 17 blockers

Please provide us with feedback regarding your experience at the activity:

YesNo
If no, please explain:
YesNoN/A
I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team
What factors beyond clinical care that effect the health of your patients does your team experience?
Attestation:

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM.

AcademicCME designates this enduring material for a maximum of 0.75 CNE Contact Hours, including 0.75 Pharmacotherapeutic Contact Hours (Provider #P0491).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
Date

MonthDayYear
Date
Credits
Should be Empty: